Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...
Tag: Pembrolizumab
Transarterial chemoembolization with pembrolizumab and levatinib improves survival in unresectable hepatocellular carcinoma
1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...
Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant ...
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Adjuvant Pembrolizumab Shows Similar Outcomes to Placebo in Resected Stage III Melanoma
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
#VisualAbstract: Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...